Abstract
A double-blind comparison was made of the effects of testosterone undecanoate (TU) and placebo on sexual potency of 29 impotent men ages 45–75. The main criteria for inclusion in the study were a reduced or nonexistent capacity to have an erection during intercourse and no clinical signs of endocrinological pathology. All patients received placebo for 2 weeks. Then TU was given at a daily dose of 120 mg to 13 patients selected at random while the other patients continued to receive placebo. After 8 weeks all patients received placebo again for 2 weeks. An improvement in sexual potency was reported by five patients given TU and eight patients given placebo, with no significant differences between the groups. Treatment with TU influenced neither the hypothalamic-pituitary-gonadal axis, as judged by levels of prolactin, LH, FSH, and the LHRH-induced LH/FSH response, nor depression, anxiety, and somatic scores or performance tests. The only specific effect of TU treatment was to decrease the total plasma testosterone level. The present findings show pharmacotherapy with androgens to be no more effective than placebo in restoring sexual potency to sexually impotent men without androgen deficiency. Further studies may be needed to elucidate fully the effects of androgen administration on psychological and endocrinological variables in such patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson, D. C. (1974). Sex-hormone-binding globulin.Clin. Endocrinol. 3: 69–95.
Benkert, O. (1977).Sexuelle Impotenz: Neuroendokrinologische und pharmakotherapeutische Untersuchungen Springer, Heidelberg.
Benkert, O. (1979). Pharmacotherapy of sexual impotence in the male.Mod. Probl. Pharm. 15 (in press).
Benkert, O., Jordan, R., Dahlen, H. G., Schneider, H. P. G., and Gammel, G. (1975). Sexual impotence: A double-blind study of LHRH nasal spray versus placebo.Neuropsychobiology 1: 203–210.
Brickenkamp, R. (1975).Test d2: Aufmerksamkeits-Belastungstest Verlag für Psychologie, Göttingen.
Coert, A., Geelen, J., de Visser, J., and van der Vies, J. (1975). The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen.Acta Endocrinol. 79: 789–800.
Franchi, F., Luisi, M., and Kicovic, P. M. (1978). Long-term study of oral testosterone undecanoate in hypogonadal males.Int. J. Androl. 1: 270–278.
Franchimont, P., Kicovic, P. M., Mattei, A., and Roulier, R. (1978). Effect of oral testosterone undecanoate in hypogonadal male patients,Clin. Endocrinol. 9: 313–320.
Friedrich, E., Jaeger-Whitegiver, E. R., Bieder, M., Halverscheidt, H., Penki, B., Pallat, P., Keller, E., and Schindler, A. E. (1974). Standardization of specific radioimmunassays for plasma estrone, estradiol, progesterone and androstenedione.J. Steroid Biochem. 5: 305.
Hamilton, M. (1959). The assessment of anxiety states by rating.Br. J. Med. Psychol. 32: 50–52.
Hirschhäuser, C., Hopkinson, C. R. N., Sturm, G., and Coert, A. (1975). Testosterone undecanoate: A new orally active androgen.Acta Endocrinol. 80: 179–187.
Horst, H.-J., Höltje, W. J., Dennis, M., Coert, A., Geelen, J., and Voigt, K. D. (1976) Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man.Klin. Wochenschr. 54: 875–879.
Joel, F. W., Schoenberg, C. K., Ilg, W., and Keller, E. (1974). Problems of optimization of double antibody radioimmunoassay of HLH, HFN and HGH. InRadioimmunassay and Related Procedures in Medicine, Vol. I, International Atomic Energy Agency, Vienna.
Mickelson, K. E., and Petra, P. H. (1974). A filter assay for the sex steroid binding protein (SBP) of human serum.FEBS Lett. 44: 34–38.
Mies, R., and Kicovic, P. M. (1977). Effects of TU administration on LH and FSH response during the standard LHRH test in healthy male volunteers.Andrologia 9(3): 233–236.
National Institute of Mental Health (1976). 028 CGI: Clinical global impressions. In Guy, W. (ed.),ECDEU Assessment Manual for Psychopharmacology, rev. ed., Rockville, Md., pp. 217–222.
Neumann, F., and Steinbeck, H. (1971). Antiandrogene: Tierexperimentelle Grundlagen und klinische Anwendungsmöglichkeiten.Internist 12: 198–205.
Nieschlag, E., Mans, J., and Kicovic, P. (1975). Plasma androgen levels in man after oral administration of testosterone or testosterone undecanoate.Acta Endocrinol. 79: 366–374.
Nieschlag, E., Cüppers, H. J., and Wickings, E. J. (1977). Influence of sex, testicular development and liver function on the bioavailability of oral testosterone.Eur. J. Clin. Invest. 7: 145.
Tremblay, R. R., and Dube, J. Y. (1974). Plasma concentration of free and non-TeBG bound testosterone in women on oral contaceptives.Contraception 10: 599–605.
Vermeulen, A., Verdonck, L., and von der Straeten, M. (1969). Capacity of the testosterone-binding globulin in human plasma and influence of specific binding of testosterone on its metabolic clearance rate.J. Clin. Endocrinol. 29: 1470–1480.
von Zerssen, D., and Koeller, D. M. (1976a).Die Beschwerden-Liste Beltz, Weinheim.
von Zerssen, D., and Koeller, D. M. (1976b).Die Befindlichkeits-Skala Beltz, Weinheim.
Wechsler, D. (1964).Die Messung der Intelligenz Erwachsener Huber, Bern-Stuttgart.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Benkert, O., Witt, W., Adam, W. et al. Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Arch Sex Behav 8, 471–479 (1979). https://doi.org/10.1007/BF01541414
Issue Date:
DOI: https://doi.org/10.1007/BF01541414